Publications
60
Citations
295
Est. group size
~15
Recurring co-author estimate
Active years
11
Publishing since 2016
Merve Hasanov's research focuses on the clinical treatment and outcomes of skin cancers, especially melanoma and cutaneous squamous cell carcinoma, with particular attention to cases that have spread to the brain (brain metastases) or resisted immune-based drug treatments. The work also touches on pancreatic cancer risk and hereditary cancer syndromes. This research is largely clinical and translational, drawing on patient outcome data, real-world treatment analyses, and clinical trials of immunotherapy combinations.
Publication output has grown markedly over the last decade, rising from about 1-4 papers per year in 2017-2021 to 12-19 in 2025-2026, indicating an increasingly active and expanding research output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report
The Oncologist · 2026
- Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2026
- CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report
Journal of the National Comprehensive Cancer Network · 2026
- Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
OncoImmunology · 2025
- Management of Cutaneous Melanoma, With a Special Focus on Desmoplastic Melanoma
American Society of Clinical Oncology Educational Book · 2025
- Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis
Acta Neuropathologica Communications · 2025
- Real-world analyses of first-line immune checkpoint inhibitors in unresectable Merkel cell carcinoma.
Journal of Clinical Oncology · 2025
- Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM).
Journal of Clinical Oncology · 2025
- The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: An NCI-SEER analysis.
Journal of Clinical Oncology · 2025
- MMAP-14 FACTORS ASSOCIATED WITH OVERALL SURVIVAL AND 90-DAY MORTALITY FOLLOWING RESECTION OF MELANOMA BRAIN METASTASES
Neuro-Oncology Advances · 2025
- New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study
Endoscopic Ultrasound · 2024
- Melanoma Brain Metastasis
Hematology/Oncology Clinics of North America · 2024
- Abstract 3605: Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma
Cancer Research · 2024
- External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
Journal of Clinical Oncology · 2023
- Data from High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer
2023
- Journal of Clinical Oncology×22
- Cancer Research×3
- Neuro-Oncology Advances×3
- OncoImmunology×2
- Clinical Lymphoma Myeloma & Leukemia×2
- Abdul Miah
Medicine · The Ohio State University
- Adam Khorasanchi
Medicine · The Ohio State University
- Andrew Johns
Medicine · The Ohio State University
- Yuanquan Yang
Medicine · The Ohio State University
- Jonathan E. Schoenhals
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile